



Contacts:

Dan Cartwright
Chief Financial Officer
Tel: (561) 961-1930
Dan.Cartwright@TherapeuticsMD.com

Investor Relations:
Lisa M. Wilson
In-Site Communications
Tel: (917) 543-9932
lwilson@insitecony.com

THERAPEUTICSMMD TO RING OPENING BELL AT NYSE

Boca Raton, FL, June 12, 2013 – TherapeuticsMD, Inc. (NYSE: TXMD), a women’s healthcare company focused on developing and commercializing products targeted exclusively for women, today announced it will visit the New York Stock Exchange to ring The Opening BellSM on June 14, 2013, marking the company’s recent listing on the NYSE.

Robert Finizio, Co-Founder and Chief Executive Officer, will ring The Opening Bell. He will be joined by Brian Bernick, M.D., Co-Founder and Chief Medical Officer; Julia Amadio, Chief Products Officer; Mitchell Krassan, Chief Strategy and Performance Officer; Dan Cartwright, Chief Financial Officer; and other members of the company’s management and advisory team.

“Our listing on the NYSE is a significant milestone for our company and we are honored to ring The Opening Bell. It marks a great achievement as we work to develop our pipeline of advanced hormone therapy products that address a critical unmet need for women seeking to alleviate menopausal symptoms and other health issues. We are excited to celebrate the future of TXMD,” Mr. Finizio said. “When we ring the bell, we look forward to sharing this celebration with all those who have contributed to our success – our customers, employees, vendors and shareholders.”

The Opening Bell will ring at 9:30 a.m. Eastern Daylight Time and will be televised on CNBC. Photos and video of the NYSE Bell Ringing Ceremony will be available, courtesy of the NYSE, on Facebook--NYSE Euronext-Official Site, Twitter at http://twitter.com/NYSE_Euronext and on the NYSE You Tube Channel -- nysetv1. Video of the bell ringing will be available for embedding/download approximately one hour after the bell rings

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is a women’s health pharmaceutical company driven to pursue the development and commercialization of advanced hormone replacement therapies. We are currently developing advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. We are evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure. More information is available at www.therapeuticsmd.com.

TherapeuticsMD[®] is a registered trademark.

###